Role of Computed Tomography in Diagnosis of Colitis as a Complication of Cancer Therapy
https://doi.org/10.35401/2541-9897-2025-10-2-127-134
Abstract
Drug therapy is an integral part of cancer treatment, which, despite its positive effects on tumor cells, can negatively affect healthy body tissues. Various treatments and antitumor drugs can cause colitis. Its complications can be serious and even result in death. Awareness and knowledge of imaging features of drug-induced colitis in cancer patients can assist in early detection of its complications and thus improve patient management and outcomes.
About the Authors
E. I. Zyablova
Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Kuban State Medical University
Russian Federation
Russian Federation
Elena I. Zyablova - Dr. Sci. (Med.), Associate Professor, Head of the Radiology Unit, Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Head of the Diagnostic Radiology Department No. 2, Kuban State Medical University; Chief Nonstaff Radiologist of the Ministry of Health of the Krasnodar Region.
ulitsa 1 Maya 167, Krasnodar, 350901
N. V. Agurina
Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Kuban State Medical University
Russian Federation
Russian Federation
Natalia V. Agurina - Assistant Professor at the Diagnostic Radiology Department No. 2, Kuban State Medical University; Radiologist, Radiology Unit, Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1.
Krasnodar
V. A. Porhanov
Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Kuban State Medical University
Russian Federation
Russian Federation
Vladimir A. Porhanov - Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences, Chief Physician, Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Head of the Oncology Department with the Thoracic Surgery Course, Faculty of Continuing Professional Development and Retraining, Kuban State Medical University.
Krasnodar
References
1. Viswanathan C, Truong MT, Sagebiel TL, et al. Abdominal and pelvic complications of nonoperative oncologic therapy. Radiographics. 2014;34(4):941–961. PMID: 25019433. https://doi.org/10.1148/rg.344140082
2. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. PMID: 29320654. https://doi.org/10.1056/NEJMra1703481
3. Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol. 2013;200(5):W468–W474. PMID: 23718569. https://doi.org/10.2214/AJR.12.9751
4. Freeman HJ. Colitis associated with biological agents. World J Gastroenterol. 2012;18(16):1871–1874. PMID: 22563166. PMCID: PMC3337561. https://doi.org/10.3748/wjg.v18.i16.1871
5. Ibarra Rovira J, Thirumurthi S, Taggart M, et al. Role of abdominal and pelvic CT scans in diagnosis of patients with immunotherapy-induced colitis. J Immunother Precis Oncol. 2022;5(2):32–36. PMID: 35664090. PMCID: PMC9153249. https://doi.org/10.36401/JIPO-21-21
6. Naing A, Hajjar J, Gulley JL, et al. Strategies for improving the management of immune-related adverse events. J Immunother Cancer. 2020;8(2):e001754. PMID: 33310772. PMCID: PMC7735083. https://doi.org/10.1136/jitc-2020-001754
7. Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38. PMID: 32382051. PMCID: PMC9728094. https://doi.org/10.1038/s41572-020-0160-6
8. Marthey L, Mateus C, Mussini C, et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis. 2016;10(4):395–401. PMID: 26783344. PMCID: PMC4946758. https://doi.org/10.1093/ecco-jcc/jjv227
9. Gupta A, De Felice KM, Loftus EV Jr, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015;42(4):406–417. PMID: 26079306. https://doi.org/10.1111/apt.13281
10. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24(15):2283–2289. PMID: 16710025. PMCID: PMC2140223. https://doi.org/10.1200/JCO.2005.04.5716
11. Itani M, Menias CO, Mellnick VM, et al. Imaging of abdominal and pelvic infections in the cancer patient. Abdom Radiol (NY). 2021;46(6):2920–2941. PMID: 33386914. PMCID: PMC7778421. https://doi.org/10.1007/s00261-020-02896-7
12. Barina AR, Bashir MR, Howard BA, Hanks BA, Salama AK, Jaffe TA. Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis. Abdom Radiol (NY). 2016;41(2):207–214. PMID: 26867901. https://doi.org/10.1007/s00261-015-0560-3
13. Pozzessere C, Mazini B, Omoumi P, et al. Immune-related adverse events induced by immune checkpoint inhibitors and CAR-T cell therapy: a comprehensive imaging-based review. Cancers (Basel). 2024;16(14):2585. PMID: 39061225. PMCID: PMC11274393. https://doi.org/10.3390/cancers16142585
14. Zyablova EI, Nefedova LN, Porkhanov VA. Radiological imaging of adverse events to immunotherapy. Journal of Oncology: Diagnostic Radiology and Radiotherapy. 2020;3(3):44–53. (In Russ.). https://doi.org/10.37174/2587-7593-2020-3-3-44-53
15. Macari M, Balthazar EJ. CT of bowel wall thickening: significance and pitfalls of interpretation. AJR Am J Roentgenol. 2001;176(5):1105–1116. PMID: 11312162. https://doi.org/10.2214/ajr.176.5.1761105
16. Latella G, Vernia P, Viscido A, et al. GI distension in severe ulcerative colitis. Am J Gastroenterol. 2002;97(5):1169–1175. PMID: 12014723. https://doi.org/10.1111/j.1572-0241.2002.05691.x
17. Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):e002435. PMID: 34172516. PMCID: PMC8237720. https://doi.org/10.1136/jitc-2021-002435
18. Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33(28):3193–3198. PMID: 26282644. PMCID: PMC5087335. https://doi.org/10.1200/JCO.2015.60.8448
19. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24(15):2283–2289. PMID: 16710025. PMCID: PMC2140223. https://doi.org/10.1200/JCO.2005.04.5716
20. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. Published correction appears in N Engl J Med. 2010;363(13):1290. PMID: 20525992. PMCID: PMC3549297. https://doi.org/10.1056/NEJ-Moa1003466
21. Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, Hricak H. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology. 2011;258(1):41-56. PMID: 21183492. https://doi.org/10.1148/radiol.10092129
22. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, November 27, 2017. https://ctep.cancer.gov/proto-coldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf
Review
For citations:
Zyablova E.I., Agurina N.V., Porhanov V.A. Role of Computed Tomography in Diagnosis of Colitis as a Complication of Cancer Therapy. Innovative Medicine of Kuban. 2025;10(2):127-134. (In Russ.) https://doi.org/10.35401/2541-9897-2025-10-2-127-134
Views:
61
Email this article 
